Home > Insider Trading > Filing (0001567619-22-008485)

Filing Details

Accession Number:: 0001567619-22-008485
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-04-13 16:09:10
Reporting Period:: 2022-04-11

Accepted Time:: 2022-04-13 16:09:10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1816736	Gemini Therapeutics Inc.	GMTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1373603	Michael Braden Leonard	65 E Cedar - Suite 2 Zionsville IN 46077		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-04-12	55,000	$1.37	270,000	No	4	P	Direct
Common Stock	Acquisiton	2022-04-11	504,487	$1.35	4,604,487	No	4	P	Indirect	Holding of BML Investment Partners, L.P.(1)
Common Stock	Acquisiton	2022-04-12	203,744	$1.42	4,808,231	No	4	P	Indirect	Holding of BML Investment Partners, L.P.(1)
Common Stock	Acquisiton	2022-04-13	191,769	$1.52	5,000,000	No	4	P	Indirect	Holding of BML Investment Partners, L.P.(1)

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	Holding of BML Investment Partners, L.P.(1)
No	4	P	Indirect	Holding of BML Investment Partners, L.P.(1)
No	4	P	Indirect	Holding of BML Investment Partners, L.P.(1)

Footnotes

Explanation of Responses:1. BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.355 to $1.40. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.3496 to $1.35. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.35 to $1.45. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.45 to $1.60. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.